Weight-Loss drug tirzepatide aims to help people keep pounds off Long-Term

NCT ID NCT06047548

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether the drug tirzepatide, given once weekly, can help people with obesity or overweight maintain weight loss they achieved during a prior diet period. About 441 participants took either tirzepatide or a placebo for 60 weeks. The goal was to see if the drug could prevent weight regain and improve related health issues like high blood pressure or sleep apnea.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirzepatide
What this could lead to: If successful, tirzepatide could offer a long-term option to help people with obesity maintain weight loss and improve related health conditions.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. Weight regain after stopping the drug is possible, and side effects like nausea or diarrhea may occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Locations

Alliance for Multispecialty Research, LLC

Norman, Oklahoma, 73069, United States
Asha Clinical Research - Munster

Hammond, Indiana, 46324, United States
Cahaba Research - Pelham

Pelham, Alabama, 35124, United States
Consano Clinical Research, LLC

Shavano Park, Texas, 78231, United States
East-West Medical Research Institute

Honolulu, Hawaii, 96814, United States
Encompass Clinical Research

Spring Valley, California, 91978, United States
Iowa Diabetes and Endocrinology Research Center

West Des Moines, Iowa, 50265, United States
L-MARC Research Center

Louisville, Kentucky, 40213, United States
New Horizon Research Center

Miami, Florida, 33165, United States
Oviedo Medical Research

Oviedo, Florida, 32765, United States
Pinnacle Clinical Research

San Antonio, Texas, 78229, United States
Prime Health and Wellness/SKYCRNG

Fayette, Mississippi, 39069, United States
Rocky Mountain Clinical Research

Idaho Falls, Idaho, 83404, United States
Rophe Adult and Pediatric Medicine/SKYCRNG

Union City, Georgia, 30291, United States
Southern California Dermatology, Inc.

Santa Ana, California, 92701, United States
Southern Endocrinology Associates

Mesquite, Texas, 75149, United States
The University of Texas Health Science Center at Houston

Bellaire, Texas, 77401, United States
Velocity Clinical Research, Dallas

Dallas, Texas, 75230, United States
Velocity Clinical Research, Westlake

Los Angeles, California, 90057, United States
WR-Clinsearch, LLC

Chattanooga, Tennessee, 37397, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.